Related Experiment Video
Updated: Aug 4, 2026
Pseudomonas aeruginosa Induced Lung Injury Model
Published on: October 29, 2014
Albumin-Based LL37 Peptide Nanoparticles as a Sustained Release System against Pseudomonas aeruginosa Lung Infection
Ling Yang1, Yang Liu1, Ning Wang1
1Department of Respiratory and Critical Care Medicine, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, China.
Insights
This study developed albumin-based nanoparticles to improve the antimicrobial peptide LL37 for treating Pseudomonas aeruginosa lung infections. The nanoparticles enhanced LL37
Area of Science:
- Biomedical Engineering
- Nanotechnology
- Infectious Diseases
Background:
- Pseudomonas aeruginosa (PA) poses a significant threat, causing pulmonary infections and lung damage.
- The antimicrobial peptide LL37 shows efficacy against PA but faces limitations like rapid clearance and low bioavailability in vivo.
Purpose of the Study:
- To develop a reduction-sensitive, albumin-based nanodrug delivery system to enhance the in vivo performance of LL37 against PA.
- To improve the therapeutic efficacy of LL37 for pulmonary infections caused by Pseudomonas aeruginosa.
Main Methods:
- Formation of an albumin-based nanodrug delivery system using intermolecular disulfide bonds for reduction sensitivity.
- Encapsulation of the cationic LL37 peptide into nanoparticles (LL37 PNP) via electrostatic interactions.
- Evaluation of sustained release, antimicrobial activity, anti-inflammatory effects in vitro, and efficacy in a murine model of acute PA lung infection.
Main Results:
- LL37 PNP demonstrated sustained release of LL37 for over 48 hours with prolonged antimicrobial effects.
- LL37 PNP significantly reduced inflammatory cytokines (TNF-α, IL-6, IL-1β) and alleviated lung damage in PA-stimulated macrophages and a murine infection model.
- LL37 PNP showed accelerated clearance of PA and improved lung infection outcomes compared to free LL37 peptide.
Conclusions:
- The developed albumin-based nanodrug delivery system effectively enhances LL37's in vivo performance against Pseudomonas aeruginosa lung infections.
- LL37 PNP exhibits potent antimicrobial and anti-inflammatory properties, offering a promising alternative for clinical treatment of PA infections.
Abstract:
Pseudomonas aeruginosa (PA) has emerged as a pressing challenge to pulmonary infection and lung damage. The LL37 peptide is an efficient antimicrobial agent against PA strains, but its application is limited because of fast clearance in vivo, biosafety concerns, and low bioavailability. Thus, an albumin-based nanodrug delivery system with reduction sensitivity was developed by forming intermolecular disulfide bonds to increase in vivo LL37 performance against PA. Cationic LL37 can be efficiently encapsulated via electrostatic interactions to exert improved antimicrobial effects. The LL37 peptide exhibits greater than 48 h of sustained released from LL37 peptide nanoparticles (LL37 PNP), and prolonged antimicrobial effects were noted as the incubation time increased. Levels of inflammatory cytokines secreted by peritoneal macrophages, including TNF-α and IL-6, were reduced significantly after LL37 PNP treatment following PA stimulation, indicating that LL37 PNP inhibits PA growth and exerts anti-inflammatory effects in vitro. In a murine model of acute PA lung infection, LL37 PNP significantly reduced TNF-α and IL-1β expression and alleviated lung damage. The accelerated clearance of PA indicates that LL37 PNP could improve PA lung infection and the subsequent inflammation response more efficiently compared with free LL37 peptide. In conclusion, this excellent biocompatible LL37 delivery strategy may serve as an alternative approach for the application of new types of clinical treatment in future.
More Related Videos
06:06Protein Kinase C-delta Inhibitor Peptide Formulation using Gold Nanoparticles
Published on: March 9, 2019
10:26P. aeruginosa Infected 3D Co-Culture of Bronchial Epithelial Cells and Macrophages at Air-Liquid Interface for Preclinical Evaluation of Anti-Infectives
Published on: June 15, 2020
